Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen-4-one in human cancer cells

Journal of Medicinal Chemistry

Volumn 49, Issue 13, 2006, Pages 3800-3808

  Barve, Vivek ^a   Ahmed, Fakhara ^b   Adsule, Shreelekha ^b   Banerjee, Sanjeev ^b   Kulkarni, Sudhir ^c   Katiyar, Prashant ^c   Anson, Christopher E ^d   Powell, Annie K ^d   Padhye, Subhash ^a,b   Sarkar, Fazlul H ^b  

^a UNIVERSITY OF PUNE   (India)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VLife Sciences Technologies   (India)

^d UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 FORMYLCHROMONE BENZOYL HYDRAZONE; 3 FORMYLCHROMONE ISONICOTINYL HYDRAZONE; 3 FORMYLCHROMONE SALICYLIC HYDRAZONE; 3 FORMYLCHROMONE THIOSEMICARBAZONE; AMINO ACID; CHROMENE DERIVATIVE; COPPER COMPLEX; FPA 120; FPA 121; FPA 122; FPA 123; FPA 124; FPA 125; FPA 126; FPA 127; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE; PLECKSTRIN; PROTEIN KINASE B; SCHIFF BASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; MULTIPLE CANCER; NONHUMAN; ONCOGENE K RAS; OXIDATION REDUCTION REACTION; PANCREAS CANCER; PROSTATE CANCER; PROTEIN DOMAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CHROMONES; COPPER; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUORESCENCE POLARIZATION; GENISTEIN; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; NF-KAPPA B; ORGANOMETALLIC COMPOUNDS; OXIDATION-REDUCTION; PANCREAS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SCHIFF BASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745639435     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051068y     Document Type: Article

References (66)

1. Knight, D. C.; Eden, J. A. A review of the clinical effects of phytoestrogens. Obstet. Gynecol. (N.Y.) 1996, 87, 897-904.
2. Mills, R.; Beeson, W.; Phillips, R.; Fraser, G. Cohort study of diet, lifestyle and prostate cancer in Adventist men. Cancer 1989, 64, 598-604.
3. WAF1, down regulation of cyclin B and induction of apoptosis in prostate cancer cells. Nutr. Cancer 1998, 32, 123-131.
4. Pagliacci, M. C.; Smacchia, M.; Migliorati, G.; Grignani, F.; Riccardi, C.; Nicoletti, I. Growth-inhibitory effects of the natural phytoestrogen genistein in MCF-7 human breast cancer cells. Eur. J. Cancer 1994, 30A, 1675-1682.
5. Kyle, E.; Neckers, E.; Takimoto, C.; Curt, G.; Bergan, R. Genistein induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol. Pharmacol. 1997, 51, 193-200.
6. Constantinou, A.; Huberman, E. Genistein as an inducer of tumor cell differentiation: Possible mechanisms of action. Proc. Soc. Exp. Biol. Med. 1995, 208, 109-115.
7. Spinozzi, F.; Pagliacci, M. C.; Migliorati, G.; et al. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk. Res. 1994, 18, 431-439.
8. Ei, Y.; Upadhyaya, S.; Bhuiyan, M.; Sarkar, F. H. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 1999, 18, 3166-3172.
9. Ei, Y.; Bhuiyan, M.; Sarkar, F. H. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int. J. Oncol. 1999, 15, 525-533.
10. Alhasan, S. A.; Pietrasczkiwicz, H.; Alonso, M. D.; Ensley, J.; Sarkar, F. H. Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr. Cancer 1999, 34, 12-19.
11. Barnes, S. Effect of genistein on in vitro and in vivo models. J. Nutr. 1995, 125, 7777-7835.
12. WAF1 upregulation and apoptosis in a NSCL cancer cell line. Nutr. Cancer 1998, 31, 184-193.
13. waf1. Clin. Cancer Res. 2001, 7, 1782-1789.
14. Davis, J. N.; Kucuk, O.; Sarkar, F. H. Genistein inhibits NF-κB activation in prostate cancer cells. Nutr. Cancer 1999, 35, 167-174.
15. Li, Y.; Sarkar, F. H. Inhibition of nuclear factor kB activation in PC-3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res. 2002, 8, 2369-2377.
16. Bors, W.; Heller, W.; Michel, C.; Saran, M. Flavanoids as antioxidants: determination of radical scavenging efficiences. Methods Enzymol. 1990, 186, 343-355.
17. Jovanvic, S. V.; Steenken, S.; Hara Y.; Simic, M. G. Reduction potentials of flavonoid and model phenoxyl radicals. Which ring in flavonoids is responsible for antioxidant activity? J. Chem. Soc., Perkin. Trans. 1996, 2, 2497-2504.
18. Rice-Evanas, C. A.; Miller, N. J.; Paganya, G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free. Radical Biol. Med. 1996, 20, 933-956.
19. Patole, J.; Dutta, S.; Padhye, S.; Sinn, E. Tuning up SOD activity of salicylaldehyde semicarbazone by heterocyclic bases. Inorg. Chim. Acta 2001, 318, 207-211.
20. Ishige, K.; Scalese, M.; Sagara, Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radical Biol. Med. 2001, 30, 433-446.
21. Saija, A.; Scalese, M.; Lanza, M.; Marzullo, D.; Bonina, F.; Casteli, F. Flavonoids as antioxidant agents: Importance of their interaction with biomembranes. Free Radical Biol. Med. 1995, 19, 483-686.
22. Silva, M. M.; Santos, M. R.; Caroco, G.; Rocha, R.; Justino, G.; Mira, L. Structure-antioxidant activity relationships. Free Radical Res. 2002, 36, 1219-1227.
23. van Acker, S. A. B. E.; van Balen, G. P.; van der Berg, D. I.; van der Vijgh, W. I. F. Influence of the iron chelators on the antioxidant activity of flavonoids. Biochem. Pharmacol. 1998, 56, 935-943.
24. Mira, L.; Fernandez, M. T.; Santos, M.; Rocha, R.; Florencio, M. H.; Jennings, K. R. Interactions of flavonoids with iron and copper ions. Free Radical Biol. Med. 2002, 36, 1199-1208.
25. Pietta, P. G. Flavonoids as antioxidants. J. Nat. Prod. 2000, 63, 1035-1051.
26. Lovejoy, D. B.; Richardson, D. R. Iron Chelators as antiproliferative agents. Curr. Med. Chem. 2003, 10, 1035-1039.
27. Pan, O.; Kleer, G. G.; Golan, K. L.; Brewer, G. Copper deficiency induced by tetrathiomolybdate suppressing tumor growth and angiogenesis. Cancer Res. 2002, 62, 4854-4859.
28. Abeysinghe, R. D.; Greene, B. T.; Haynes, R. The p-53 independent apoptosis mediated by tachpyridine. Carcinogenesis 2001, 22, 1607-1614.
29. Fan, O.; Iyer, J.; Zhu, S. Inhibition of N-myc expression and induction of apoptosis by iron chelator, in human neuroblastoma cells. Cancer Res. 2001, 61, 1073-1079.
30. Liu, G.Y.; Frank, N.; Bartsch, H.; Lin, J. K. Induction of apoptosis by thuramdisulfides, the reactive metabolites of dithiocarbamates through coordinate modulation of NF-κB, c-fos/c-jun and p-53 proteins. Mol. Carconog. 1998, 22, 235-246.
31. von, Angerer E., Keppler, B. K., Eds. Metal Complexes in Cancer Chemotherapy, VCH: Weinham, Germany, 1993: pp 73-80.
32. Fasmon J.; Heinisch G.; Holzer W. Thiosemicarbazone derivatives of pyridazinecarbaldehydes and alkyl pyridazinyl ketones. Heterocycles 1989, 29, 1399-1408.
33. West, D. X.; Padhye, S. B.; Sonawane, P. B. Structural and physical correlations in the biological properties of transition metal N-heterocyclic thiosemicarbazones. Struct. Bonding 1991, 76, 1-51.
34. Nawar, N.; Hosny, N. M. Synthesis, spectral and antimicrobial activity studies of o-aminoacetophenone o-hydroxybenzoylhydrazone complexes. Trans. Met. Chem. 2000, 25, 1-8.
35. Garg, B. S.; Singh, P. K.; Sharma, J. L. Synthesis and characterization of transition metal(II) complexes of salicylaldehyde-2-furoylhydrazone. Synth. React. Inorg. Met.-Org. Chem. 2000, 30, 803-813.
36. Sangeetha, N. R.; Pal, S. A family of dinuclear vanadium(V) complexes containing the {OV (μ-O) VO} 4+ core: Syntheses, structures, and properties. Bull. Chem. Soc. Jpn. 2000, 73, 357-363.
37. Kong, A. N.; Owuor, E.; Yu, R.; Induction of xenobiotics enzymes by the MAP kinase pathway and the antioxidant or electrophile response element. Drug Metab. Rev. 2001, 33, 255-271.
38. Yu, R.; Lei, W.; Madelkar, S.; Weber, M. J.; Der, C. J.; Wu, J.; Kong, A. T. Role of nitrogen activated kinase pathway in the induction of phase detoxifying enzymes by chemicals. J. Biol. Chem. 1999, 274, 27545-27552.
39. Hathaway, B. J.; Billing, D. E. Electronic properties and stereochemistries of mononuclear complexes of copper(II) ions. Coord. Chem. Rev. 1970, 5, 143-207.
40. Lever, A. B. P. Inorganic Electronic Spectroscope, 2nd ed.; Elsevier: New York, 1984.
41. West, D. X.; Salberg, M. M.; Bain, G. A.; Liberia, A. E.; Valdes-Martinez, J.; Hernandez-Ortega, S. J. Nickel(II) and copper(II) complexes of 5-substituted formylthiophene thiosemicarbazone. Transition Met. Chem. (Dordrecht, Neth.) 1996, 21, 206-209.
42. 4-substituted thiosemicarbazones. Polyhedron 1995, 14, 1681-1693.
43. Earnshaw, A. An Introduction to Magnetochemistry; Academic Press: London, 1968.
44. Mabbs, F. E.; Machin, D. J. Magnetism and Transition Metal Complexes; Chapman and Hall: London, 1973.
45. Kato, M.; Fanning, J. C.; Jonassen, H. B. Copper complexes of subnormal magnetic moments. Chem. Rev. 1969, 64, 99-125.
46. Diaz, A.; Cao, R.; Fargoso, A.; Sanchez, I. Interpretation of SOD-like activity of a series of copper complexes with thiosemicarbazones. Inorg. Chem. Commun. 1999, 2, 358-360.
47. Sonawane, P.; Chikate, R.; Kumbhar, A.; Padhye, S.; Doedens, R. J. Inequivalent coordination of thiosemicarbazone ligands in Co(III) and Cr(III) complexes. Polyhedron 1994, 13, 395-401.
48. LCk protein tyrosine kinase. Cell. Mol. Biol. Lett. 2005, 10, suppl 2.
49. Milburn, C. C.; Deak, M.; Kelley, S. M.; Price, N. C.; Alessi, D. R.; van Aalten, D. M. F. Biochemistry, binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochemistry 2003, 375, 531-538.
50. MDS 1.0 Molecular Design Suite; VLife Sciences Technologies, Pvt Ltd.: Pune, India, 2003.
51. Yang, J.; Cron, P.; Thompson, V.; Good, V.; Hess, D.; Hemmings, B.; Barford, D. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol. Cell 2002, 9, 1227-1240.
52. Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B. A.; Barford, D. Crystal structure of an activated Akt/protein kinase B ternary complex with Gsk-3 peptide and AMP-Pnp. Nat. Struct. Biol. 2002, 9, 940-944.
53. Chang, G.; Guida, W. C.; Still, W. C. An internal coordinate Monte Carlo method for searching conformational space. J. Am Chem. Soc. 1989, 111, 4379-4386.
54. Halgren, T. A. Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data and empirical rules. J. Comp. Chem. 1996, 17, 616-641.
55. Halgren, T. Maximally diagonal force constants in dependent angle-bending coordinates. II. Implications for the design of empirical force fields. J. Am. Chem. Soc. 1990, 112, 4710-4723.
56. Padhye, S.B.; Afrasiabi, Z.; Sinn, E.; Fok, J.; Mehta, K.; Rath, N. Antitumor metallothiosemicarbazonates: Structure and antitumor activity of palladium complex of phenanthrequinone thiosemicarbazone. J. Inorg. Chem. 2005, 44, 1154-1156.
57. Hill, Z. D.; MacCarthy, P. Novel approach to Job's method. J. Chem. Educ. 1986, 63, 162-167.
58. Hathway, B. J. Comprehensive Coordination Chemistry, Pergamon Press: London, 1987; vol 5, pp 533-774.
59. Alessi, D. R.; Caudwell, F. B.; Andjelkovic, M.; Hemmings, B. A.; Cohen, P. Molecular basis for the substrate specificity of protein kinase B; comparison with MAP Kinase 1 and p70 Sb kinase. FEBS Lett. 1996, 399, 333-338.
60. Alessi, D. R.; Cohen, P.; Ashworth, A.; Cowley, S.; Leevers, S. J.; Marshall, C. J. Assay and expression of mitogen activated protein kinase, MAP kinase and Raf. Methods Enzymol. 1995, 255, 279-290.
61. Kane, L. P.; Shapiro, V. S.; Stokoe, D.; Weiss, A.; Induction of NF-κ by the Akt/PKB kinase. Curr. Biol. 1999, 9, 601-604.
62. Reusch, H. P.; Zimmermann, S.; Schaefer, M.; Paul, M.; Moelling, K.; Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J. Biol. Chem. 2001, 276, 33630-33637.
63. Mohammad, R. M.; Al-Katib, A.; Pettit, G. R.; Vaitkevicius, V. K.; Joshi, U.; Adsay, V.; Majumdar, A. P.; Sarkar, F. H. An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: Potential application for preclinical studies. Clin. Cancer Res. 1998, 4, 887-894.
64. Li, Y.; Bhagat, S.; Ellis, K. L.; Kucuk, O.; Deorge, D. R.; Abrams, J.; Cher, M. L.; Sarkar, F. H. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 2004, 6, 354-363.
65. Hillman, G. G.; Wang, Y.; Kucuk, O.; Che, M.; Doerge, D. R.; Yudelev, M.; Joiner, M. C.; Marples, B.; Forman, J. D.; Sarlar, F. H. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol. Cancer Ther. 2004, 30, 1271-1279.
66. Banerjee, S.; Zhang, Y.; Ali, S.; Bhuiyan, M.; Wang, Z.; Chaio, P. J.; Philip, P. A.; Abbruzzese, J.; Sarkar, F. H. Molecular Evidence for Increased Antitumor Activity of Gemcitabine by Genistein In vitro and In vivo Using an Orthotopic Model of Pancreatic Cancer. Cancer Research. 2005, 65, 9064-9072.